1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors

Fabrizio Micheli, Paolo Cavanni, Roberto Arban, Roberto Benedetti, Barbara Bertani, Michela Bettati, Letizia Bettelini, Giorgio Bonanomi, Simone Braggio, Anna Checchia, Silvia Davalli, Romano Di Fabio, Elettra Fazzolari, Stefano Fontana, Carla Marchioro, Doug Minick, Michele Negri, Beatrice Oliosi, Kevin D. Read, Ilaria SartoriGiovanna Tedesco, Luca Tarsi, Silvia Terreni, Filippo Visentini, Alessandro Zocchi, Laura Zonzini

    Research output: Contribution to journalArticlepeer-review

    35 Citations (Scopus)


    The discovery of new highly potent and selective triple reuptake inhibitors is reported. The new classes of 1-(ary1)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes are described together with detailed SA R. Appropriate decoration of the scaffolds was achieved with the help of a triple reuptake inhibitor pharmacophore model detailed here. Selected derivatives showed good oral bioavailability ( > 30%) and brain penetration (B/B > 4) in rats associated with high in vitro potency and selectivity at SERT, NET, and DAT. Among these compounds, microdialysis and in vivo experiments confirm that derivative 15 has an appropriate developability profile to be considered for further progression.

    Original languageEnglish
    Pages (from-to)2534-2551
    Number of pages18
    JournalJournal of Medicinal Chemistry
    Issue number6
    Publication statusPublished - 25 Mar 2010

    Cite this